Efficacy and safety of rituximab for intractable immunogenic neurological disorder in childre
Not Applicable
Recruiting
- Conditions
- neuromyelitis optica (NMO), opsoclonus-myoclonus syndrome (OMS)
- Registration Number
- JPRN-UMIN000009421
- Lead Sponsor
- Department of Pediatrics, Kobe Universtiy Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
The patients 1) are affected for infectious disease, 2) are recieved live vaccine within 4weeks, 3) are suffered from heart, lung, liver and kidney disease, 4) have the allergy for rituximab, 5) are ruled unfit to this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method